5-HT2C Antagonist - Pipeline Insight 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “5-HT2C Antagonist -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.‘5-HT2C Antagonist - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT2C Antagonist development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:ClinicalNon-clinicalInactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for 5-HT2C Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. 5-HT2C Antagonist - Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for 5-HT2C Antagonist
4. Comparative Analysis
5. 5-HT2C Antagonist Pipeline Products in Clinical Stages
6. 5-HT2C Antagonist Pipeline Products in Non-clinical Stages
7. Therapeutic Assessment: Active ProductsPipeline Assessment by Route of AdministrationPipeline Assessment by Stage and Route of AdministrationPipeline Assessment by Molecule TypePipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
Companies MentionedFabre-Kramer PharmaceuticalsSumitomo Dainippon PharmaAnaMar ABLundbeck A/SS1 PharmaceuticalsAltus Formulation IncServierJanssen-Cilag
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/lp8tts/5ht2c_antagonist?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005351/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/19/2018 07:36 AM/DISC: 12/19/2018 07:36 AM